Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neckThomas Kuhnt, Jürgen Dunst, Kathrin Dellas et al.|Strahlentherapie und Onkologie|2017Cited by 8
Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.Thomas Kuhnt, Juergen Dunst, Andreas Schreiber et al.|Journal of Clinical Oncology|2013Cited by 3
8501 ORAL Phase ll-trial of Concomitant Hyperfractionated-accelerated Radiotherapy (HART) With Cisplatin (Cis) Plus Cetuximab (Cet) for Locoregionally Advanced Inoperable Squamous Cell Head and Neck Cancer – Early Response and Acute ToxicitiesThomas Kuhnt, Juergen Dunst, Andreas Schreiber et al.|European Journal of Cancer|2011Cited by 0
Phase II-trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell head and neck cancer: 5-year end resultsThomas Kuhnt, Juergen Dunst, Michael Richter et al.|Annals of Oncology|2016Cited by 0